Study of the Stability of Factor VIII Activity in Human Plasma for Fractionation When Modeling Deviations in the Storage and Transportation Temperature Conditions

The European Pharmacopoeia requires that the transportation and storage of human plasma for fractionation should be carried out at –20 °C or below, while allowing for some deviations in the temperature regime. The current Russian regulatory documentation requires the transportation and storage of pl...

Full description

Saved in:
Bibliographic Details
Main Authors: A. A. Gorodkov, A. L. Poptsov, A. L. Khokhryakov
Format: Article
Language:Russian
Published: Ministry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» 2020-09-01
Series:Биопрепараты: Профилактика, диагностика, лечение
Subjects:
Online Access:https://www.biopreparations.ru/jour/article/view/285
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849242937081200640
author A. A. Gorodkov
A. L. Poptsov
A. L. Khokhryakov
author_facet A. A. Gorodkov
A. L. Poptsov
A. L. Khokhryakov
author_sort A. A. Gorodkov
collection DOAJ
description The European Pharmacopoeia requires that the transportation and storage of human plasma for fractionation should be carried out at –20 °C or below, while allowing for some deviations in the temperature regime. The current Russian regulatory documentation requires the transportation and storage of plasma intended for the production of labile protein preparations (blood clotting factors) at  –30 °C or lower. However, acceptable deviations from the temperature regime are not specified, which creates certain difficulties in their assessment by an authorised person during plasma batch release. The main tool in risk assessment is in-process control of factor VIII activity in plasma stored at inadequate temperature, which entails significant financial costs. The aim of the study was to assess stability of factor VIII activity in human plasma for fractionation when modeling deviations in the storage and transportation temperature regime and to assess the possibility of amending the regulatory documentation requirements. Materials and methods: only full individual doses of plasma obtained by apheresis were used in the experiments. The tests were performed under simulated high temperature conditions with accurate continuous recording of temperature by a measuring system. An automatic coagulation analyser was used to determine factor VIII activity. Quantitative evaluation of the results was carried out by comparing factor VIII activity in the plasma before freezing and in the tested plasma. Statistical processing of data was performed by descriptive statistics methods using Microsoft Excel 2007 applications. Results: no significant effect of short-term deviations in the storage temperature on the stability of factor VIII activity in human plasma for fractionation was observed. Conclusions: the obtained data can be used as a rationale for introducing changes in the official requirements for the storage and transportation temperature regime for human plasma for fractionation, as well as for including details of acceptable short-term deviations of the storage and transportation temperature regime in the regulatory documentation.
format Article
id doaj-art-8d8b7edb6dee41108a44a54304a4e4c3
institution Kabale University
issn 2221-996X
2619-1156
language Russian
publishDate 2020-09-01
publisher Ministry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»
record_format Article
series Биопрепараты: Профилактика, диагностика, лечение
spelling doaj-art-8d8b7edb6dee41108a44a54304a4e4c32025-08-20T03:59:39ZrusMinistry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»Биопрепараты: Профилактика, диагностика, лечение2221-996X2619-11562020-09-0120320220710.30895/2221-996X-2020-20-3-202-207220Study of the Stability of Factor VIII Activity in Human Plasma for Fractionation When Modeling Deviations in the Storage and Transportation Temperature ConditionsA. A. Gorodkov0A. L. Poptsov1A. L. Khokhryakov2Russian Medical Research and Production Center “Rosplasma” Federal Medical and Biological AgencyRussian Medical Research and Production Center “Rosplasma” Federal Medical and Biological AgencyRussian Medical Research and Production Center “Rosplasma” Federal Medical and Biological AgencyThe European Pharmacopoeia requires that the transportation and storage of human plasma for fractionation should be carried out at –20 °C or below, while allowing for some deviations in the temperature regime. The current Russian regulatory documentation requires the transportation and storage of plasma intended for the production of labile protein preparations (blood clotting factors) at  –30 °C or lower. However, acceptable deviations from the temperature regime are not specified, which creates certain difficulties in their assessment by an authorised person during plasma batch release. The main tool in risk assessment is in-process control of factor VIII activity in plasma stored at inadequate temperature, which entails significant financial costs. The aim of the study was to assess stability of factor VIII activity in human plasma for fractionation when modeling deviations in the storage and transportation temperature regime and to assess the possibility of amending the regulatory documentation requirements. Materials and methods: only full individual doses of plasma obtained by apheresis were used in the experiments. The tests were performed under simulated high temperature conditions with accurate continuous recording of temperature by a measuring system. An automatic coagulation analyser was used to determine factor VIII activity. Quantitative evaluation of the results was carried out by comparing factor VIII activity in the plasma before freezing and in the tested plasma. Statistical processing of data was performed by descriptive statistics methods using Microsoft Excel 2007 applications. Results: no significant effect of short-term deviations in the storage temperature on the stability of factor VIII activity in human plasma for fractionation was observed. Conclusions: the obtained data can be used as a rationale for introducing changes in the official requirements for the storage and transportation temperature regime for human plasma for fractionation, as well as for including details of acceptable short-term deviations of the storage and transportation temperature regime in the regulatory documentation.https://www.biopreparations.ru/jour/article/view/285human plasma for fractionationfactor viii activitystabilityindividual plasma doseapheresisrisk analysis
spellingShingle A. A. Gorodkov
A. L. Poptsov
A. L. Khokhryakov
Study of the Stability of Factor VIII Activity in Human Plasma for Fractionation When Modeling Deviations in the Storage and Transportation Temperature Conditions
Биопрепараты: Профилактика, диагностика, лечение
human plasma for fractionation
factor viii activity
stability
individual plasma dose
apheresis
risk analysis
title Study of the Stability of Factor VIII Activity in Human Plasma for Fractionation When Modeling Deviations in the Storage and Transportation Temperature Conditions
title_full Study of the Stability of Factor VIII Activity in Human Plasma for Fractionation When Modeling Deviations in the Storage and Transportation Temperature Conditions
title_fullStr Study of the Stability of Factor VIII Activity in Human Plasma for Fractionation When Modeling Deviations in the Storage and Transportation Temperature Conditions
title_full_unstemmed Study of the Stability of Factor VIII Activity in Human Plasma for Fractionation When Modeling Deviations in the Storage and Transportation Temperature Conditions
title_short Study of the Stability of Factor VIII Activity in Human Plasma for Fractionation When Modeling Deviations in the Storage and Transportation Temperature Conditions
title_sort study of the stability of factor viii activity in human plasma for fractionation when modeling deviations in the storage and transportation temperature conditions
topic human plasma for fractionation
factor viii activity
stability
individual plasma dose
apheresis
risk analysis
url https://www.biopreparations.ru/jour/article/view/285
work_keys_str_mv AT aagorodkov studyofthestabilityoffactorviiiactivityinhumanplasmaforfractionationwhenmodelingdeviationsinthestorageandtransportationtemperatureconditions
AT alpoptsov studyofthestabilityoffactorviiiactivityinhumanplasmaforfractionationwhenmodelingdeviationsinthestorageandtransportationtemperatureconditions
AT alkhokhryakov studyofthestabilityoffactorviiiactivityinhumanplasmaforfractionationwhenmodelingdeviationsinthestorageandtransportationtemperatureconditions